Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).

doi:10.1158/1078-0432.CCR-12-3919

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2013

Slingluff Craig L, Petroni Gina R, Molhoek Kerrington R, Brautigan David L, Chianese-Bullock Kimberly A, Shada Amber L, Smolkin Mark E, Olson Walter C, Gaucher Alison, Chase Cheryl Murphy, Grosh William W, Weiss Geoffrey R, Wagenseller Aubrey G, Olszanski Anthony J, Martin Lainie, Shea Sofia M, Erdag Gulsun, Ram Prahlad, Gershenwald Jeffrey E, Weber Michael J

Abstract excerpt

PURPOSE: A CTEP-sponsored phase II trial was conducted to evaluate safety and clinical activity of combination therapy with CCI-779 (temsirolimus) and bevacizumab in patients with advanced melanoma. EXPERIMENTAL DESIGN: Patients with unresectable stage III to IV melanoma were treated intravenously with temsirolimus 25 mg weekly and bevacizumab 10 mg every 2 weeks. Adverse events were recorded using CTCAE v3.0....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bevacizumab

Share to Biopsy

Share to GTP Phosphohydrolases

Share to Ki-67 Antigen

Share to Phosphoproteins

Share to Sirolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 23620404
DOI: 10.1158/1078-0432.CCR-12-3919
PMCID: PMC3700572

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).PMID 23620404Read ↗

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.Semantic proximity Read ↗

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.Semantic proximity Read ↗

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.Semantic proximity Read ↗

Targeted Therapy for Melanomas Without BRAF V600 Mutation.Semantic proximity Read ↗

The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.Semantic proximity Read ↗

Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.Semantic proximity Read ↗

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.Semantic proximity Read ↗

A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.Semantic proximity Read ↗

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.Semantic proximity Read ↗

Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.Semantic proximity Read ↗

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.Semantic proximity Read ↗

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.